---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-043559"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2026-06-16T20:30:16+00:00"
generated_at: "2026-06-16T20:35:22.401754+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arvinas, Pfizer, Rigel close VEPPANU license deal; $70M upfront received

## Summary
- HSR waiting period terminated June 11, 2026, making License Agreement effective.
- Rigel paid $70M aggregate upfront to Arvinas and Pfizer, split evenly.
- Additional $15M payable upon successful completion of transition activities.
- Up to $320M in development, regulatory, and commercial milestones plus tiered royalties.
- Milestones and royalties replace unearned payments from Pfizer to Arvinas under prior collaboration.

## SEC filing metadata
- accession: 0001628280-26-043559
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2026-06-16T20:30:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000162828026043559/0001628280-26-043559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000162828026043559/arvn-20260611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-043559
- JSON: https://secwatch.observer/filing/0001628280-26-043559.json
- Plain text: https://secwatch.observer/filing/0001628280-26-043559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.